Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.38 |
| ▸ | GOT1 | P17174 | 1/20 | 0.38 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.38 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 5/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906918 | 0.81 | AADAT (0.36) | AADATGOT1KYAT1KYAT3 | |
| SCHEMBL8081919 | 0.76 | NPY1R (0.51) | — | |
| SCHEMBL7753002 | 0.74 | CCKBR (0.37) | XIAP | |
| SCHEMBL8081902 | 0.74 | KMT2A (0.37) | — | |
| SCHEMBL8783598 | 0.73 | ACE (0.44) | ACEMME | |
| SCHEMBL8837676 | 0.72 | ACE (0.43) | ACEMMEAADATGOT1KYAT1 | |
| Hydrochloric Acid SCHEMBL7487323 | 0.72 | ACE (0.43) | ACEMMEAADATGOT1KYAT1 | |
| SCHEMBL8795891 | 0.71 | GABRP (0.55) | — | |
| SCHEMBL7541608 | 0.70 | SCN9A (0.46) | SCN9A | |
| SCHEMBL8808190 | 0.69 | MAPT (0.43) | XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-01 | — | — | US | claimed |
| US-6096885-A | EXHIBIT AGONIST ACTIVITY FOR CCK-A RECEPTORS THEREBY ENABLING THEM TO MODULATE THE HORMONES GASTRIN AND CHOLECYSTOKININ IN MAMMALS. | GLAXO WELLCOME INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0785944-A1 | ACYL AMINO ACETAMIDE DERIVATIVES WITH AGONIST ACTIVITY FOR CCK-A RECEPTORS | GLAXO WELLCOME INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011940-A1 | ACYL AMINO ACETAMIDE DERIVATIVES WITH AGONIST ACTIVITY FOR CCK-A RECEPTORS | GLAXO WELLCOME INC. (US) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS2 | ACE 525/4885MME 1705/4885AADAT 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.